In the SURMOUNT-OSA trials, people with moderate-to-severe sleep apnea who took tirzepatide for a year had about 25 to 29 fewer breathing interruptions per hour of sleep, roughly half of what they started with. Between 42% and 50% of them reached the trial's definition of resolution: an apnea-hypopnea index (AHI) under 5, or 5 to 14 with little daytime sleepiness (Malhotra et al., New England Journal of Medicine, 2024, DOI (external link)).
Read that result the other way round and the other half still had apnea after a year and nearly 20% weight loss. If you use CPAP and you're losing weight on a GLP-1, your machine and your sleep doctor both need to keep up with a changing body. This guide covers why you shouldn't put the mask away on your own, what changes as the weight comes off, how retesting works, and how the sleep apnea diagnosis affects coverage for Zepbound.
What the trials actually showed
Tirzepatide, sold as Zepbound, was approved by the FDA on December 20, 2024 to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, together with a reduced-calorie diet and more physical activity. As of September 2026 it is still the only medication approved to treat OSA. A second drug, Apnimed's AD109 pill, is under FDA review, with a decision date of February 28, 2027.
The approval rests on two 52-week trials run together as SURMOUNT-OSA:
| Trial 1: not using PAP | Trial 2: already using PAP | |
|---|---|---|
| Starting AHI (events per hour) | 51.5 | 49.5 |
| Change in AHI, tirzepatide | −25.3 (about −51%) | −29.3 (about −59%) |
| Change in AHI, placebo | −5.3 | −5.5 |
| Weight change, tirzepatide | −17.7% | −19.6% |
| Reached resolution, tirzepatide vs. placebo | 42% vs. 16% | 50% vs. 14% |
Tirzepatide also lowered blood pressure, inflammation (hsCRP), and "hypoxic burden," a measure of how much oxygen levels fall during the night. A later analysis found that the drop in inflammation and insulin resistance was partly explained by improvement in the apnea itself, not only by weight loss. The authors concluded that treating both the sleep apnea and the obesity is likely needed to get the full cardiometabolic benefit (Malhotra et al., Nature Medicine, 2026, DOI (external link)).
One design detail matters for CPAP users. In trial 2, participants stopped using PAP for 7 days before each sleep study, so the tests measured their untreated apnea. The trial showed what the drug does to the apnea. It did not test whether people could safely stop CPAP for good.
Why you shouldn't stop CPAP on your own
The American Academy of Sleep Medicine's advice to clinicians is direct: "CPAP should not be discontinued without proper reassessment," and tirzepatide is meant as "an adjunctive tool," not a replacement for CPAP (AASM (external link), September 2025). There are several reasons.
- Feeling better is not the same as being better. Many people feel more rested as they lose weight. OSA can still be moderate or severe while you feel fine, and a partner's report of "no more snoring" does not tell you what your oxygen is doing.
- Resolution was the outcome for about half of participants, not all. Even with nearly 20% weight loss, many people in the trials still had clinically significant OSA at one year.
- Weight loss takes months. The trials measured results at 52 weeks. During the months in between, your apnea is still there, just smaller.
- Weight can come back. If you stop the medication, weight regain is common, and the apnea tends to come back with it. A long-running Wisconsin cohort found that each 10% of weight gained predicted about a 32% rise in AHI, and each 10% lost predicted about a 26% fall (Peppard et al., JAMA, 2000, DOI (external link)). Our guide to stopping a GLP-1 covers what happens to weight after stopping.
The practical rule: keep using CPAP every night while you lose weight, and let a repeat sleep test decide when you can use less of it or stop.
What changes as the weight comes off
Your pressure needs usually drop. Less tissue around the neck and airway means less pressure is needed to hold it open. If you have an automatic machine (APAP), it adjusts pressure breath by breath within a range your clinician sets. AASM guidelines recommend either CPAP or APAP for ongoing treatment (Patil et al., Journal of Clinical Sleep Medicine, 2019, DOI (external link)). APAP can only work within its set range, though. If you use a fixed-pressure CPAP, the setting chosen at your original titration may now be more than you need.
Signs your settings may need a look:
- The air feels harder to breathe out against than it used to
- More mask leaks, or a mask that suddenly fits differently
- Swallowing air, burping, or bloating in the morning. That is easy to blame on the GLP-1, so it's worth mentioning to both your prescriber and your sleep team.
- Dry mouth, or waking with the mask off
- Your machine's app showing a rising AHI or big leak numbers
None of these means you should change the settings yourself. Pressure changes are a prescription, and your sleep clinic or equipment supplier can often adjust a modern machine remotely once your clinician approves it.
Your mask may need refitting. Faces slim as weight comes off, especially cheeks, jaw, and neck. A mask sized before treatment can start to leak, and a leaking mask delivers less pressure and wakes you up. Ask your equipment supplier for a refit. Masks are replaced on a schedule anyway (Medicare's PAP coverage rule, for example, allows a new full face mask every 3 months), so a new size may cost little or nothing.
Your machine data is useful, with a limit. Most modern machines record nightly use, leaks, and a "residual AHI," which is the number of events that still get through while you wear the mask. Your sleep team can review this remotely, and AASM guidelines recommend ongoing follow-up of usage and effectiveness data for everyone on PAP (Patil et al., 2019). But residual AHI only tells you how well CPAP is working. It cannot tell you how much apnea you would have without it. Only a sleep test done without the machine answers that question.
When and how retesting happens
The American Academy of Sleep Medicine has long advised a follow-up sleep study for CPAP users after substantial weight loss, which it defines as about 10% of body weight (Epstein et al., Journal of Clinical Sleep Medicine, 2009, PubMed (external link)). On a GLP-1 many people pass that point within the first several months, so it is worth raising at your next visit rather than waiting for your annual check-in.
What retesting usually looks like:
- Your sleep clinician decides the timing. This is often after weight loss has been meaningful and fairly stable, not in the middle of rapid loss.
- You may be asked to skip CPAP before the test, so it measures your apnea without treatment. How long you go without it, and whether that is safe for you, is your clinician's call. People with severe OSA, heart disease, or jobs where drowsiness is dangerous may need a different plan.
- The test may be at home or in a lab. A home sleep apnea test is common for straightforward cases, and an in-lab study is used when things are more complicated. Our guide to getting a sleep study explains both and how AHI is graded.
- The result decides the next step. Depending on the new AHI and your symptoms, your clinician may keep you on CPAP at lower settings, switch you to a different treatment such as an oral appliance for milder OSA, or, if the apnea has resolved, stop CPAP and plan to recheck if weight or symptoms change.
Coverage for a repeat study usually needs a documented reason, and "substantial weight loss on treatment" is a standard one. Ask your clinician to note your weight change when ordering it.
Coverage: how the OSA diagnosis affects Zepbound
Because Zepbound is FDA-approved for OSA, a documented diagnosis of moderate-to-severe OSA can open coverage routes that weight management alone does not. Details change often, so everything below is as of September 2026.
- Medicare. Medicare Part D is barred by law from covering drugs used only for weight loss, but plans can cover GLP-1s for other FDA-approved uses, and sleep apnea is one of them (KFF (external link), updated May 2026). Coverage for OSA still depends on your plan's formulary and usually on prior authorization with a sleep study. Separately, the temporary Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) offers eligible Part D enrollees a $50 monthly copay for certain GLP-1s, including the Zepbound KwikPen, when used for obesity. The two routes are separate. Our guide to the push for Medicare GLP-1 coverage covers the Bridge in more detail.
- Commercial insurance. Some plans that exclude weight-loss drugs will cover Zepbound for OSA, and some will not. Prior authorization usually asks for a sleep study showing moderate-to-severe OSA (AHI of 15 or more) and a BMI of 30 or more. UnitedHealthcare's commercial policy (effective September 1, 2026), for example, requires both, plus either continued OSA symptoms despite regular PAP use (at least 4 hours a night on at least 70% of nights) or a reason PAP isn't an option. The levers are the ones in our insurance coverage guide: formulary, prior authorization, and diagnosis.
- Reauthorization. Prior authorizations have to be renewed and may ask for evidence the drug is helping. Under the UnitedHealthcare policy, the first approval lasts 6 months, and renewal for people not on PAP needs a sleep study showing the AHI has fallen. Keep your sleep study reports, weight records, and machine data. They are what a renewal usually asks for.
- Your CPAP coverage is separate. Medicare ties continued payment for PAP equipment to documented use: at least 4 hours a night on 70% of nights in a 30-day stretch during the first 3 months, confirmed at a clinician re-evaluation. If you stop using CPAP without a new sleep study behind the decision, you can lose equipment coverage and have a harder time getting it back if your apnea returns.
In short: ask for a repeat sleep test once you've lost about 10% of your weight, and let that test, not how rested you feel, decide what happens to your CPAP. For more on sleep and GLP-1s, see sleep quality on a GLP-1.
This article is general education, not medical advice. Do not change your CPAP settings or stop CPAP without talking to your sleep clinician, and confirm coverage details with your plan, since they change often. Research findings above are attributed to PubMed-indexed articles with DOI links.